Feed BMRN
BM

BioMarin Pharmaceutical

BMRN · NASDAQ

$66.41 -0.14% (-$0.09)
1M -1.44%
Market Cap $12.8B
P/E Ratio 175.90x
Div. Yield -
ROE 1.18%

Bulios Fair Price

$68.43

3.0% upside

Current Price

$66.41

Undervalued Fair Value Overvalued

According to Bulios Fair Price, BMRN is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
36 /100
Fair
P/E 175.90x
P/B 2.03x
EV/EBITDA 41.91x
Growth
94 /100
Growing
EPS growth 33.89%
Book val. growth 9.76%
Rev. growth 15.40%
Profitability
64 /100
Moderate
Gross margin 75.55%
FCF margin 21.51%
Net margin 2.14%
Quality
7 /100
Poor
ROIC 1.25%
Asset turnover 0.29x
ROE 1.18%
Debt
43 /100
Moderate
Debt/Equity 0.66x
Net debt/EBITDA 8.63x
Current ratio 2.39x
Stability
42 /100
Moderate
Beta 0.24x
Profitable years 4
Rev. volatility 2.55%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BMRN
Online

About the company

BioMarin Pharmaceutical Inc. (BMRN) is an American biopharmaceutical company specializing in the research, development, and manufacturing of drugs for rare genetic diseases and rare disorders. With a broad portfolio of medicines serving the needs of patients with genetically determined disorders, BioMarin is a leading innovator in the treatment of genetic diseases. The company is known for its pioneering therapeutic approaches and longstanding commitment to patients with rare diseases. BioMarin also actively invests in the research and development of new drugs and therapies to improve the quality of life for patients. BioMarin Pharmaceutical Inc. (BMRN) shares could be suitable for investors looking to invest in the biopharmaceutical sector with a focus on treating rare genetic diseases and innovative research and development.

Sector

Healthcare

Industry

Biotechnology

CEO

Alexander Hardy

Employees

3,221

Headquarters

San Rafael

Upcoming events

26 OCT

Earnings

Upcoming earnings report

41d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.